Ahmet Ziya Şahin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ahmet Ziya Şahin has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Şengül Kocamer Şahin
Department of Psychiatry, Adana Medical Faculty, Adana City Hospital, University of Health Sciences, Adana 01230, Türkiye
4 shared publications - Ahmet Ekmekci
Department of Cardiology, Faculty of Medicine, Memorial Göztepe Hospital, Bahçeşehir University, 34349 İstanbul, Türkiye
3 shared publications - Ali İlter
Nephrology Clinic, Kütahya Evliya Çelebi Education and Research Hospital, 43040 Kütahya, Türkiye
3 shared publications - Alper Tuna Güven
Faculty of Medicine, Department of Internal Medicine, Division of General Internal Medicine, Marmara University, İstanbul, Türkiye
3 shared publications - Arda Erdut
Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, 06100 Ankara, Türkiye
3 shared publications - Asena Serap Karatutlu
Nephrology Clinic, Bursa Yuksek Ihtisas Training and Research Hospital, 16310 Bursa, Türkiye
3 shared publications
Latest Publications
- Open Access
- 23 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (15) , 5758
Hyperkalemia Risk After Finerenone Initiation in Diabetic Kidney Disease with Elevated Baseline Potassium: A Multicenter Cohort Study
Background/Objectives: Finerenone improves cardiovascular and renal outcomes in diabetic kidney disease (DKD), but hyperkalemia remains a key safety concern. Patients with elevated baseline potassium levels (≥4.9 mEq/L) are largely excluded from clinical trials, and real-world data in this population are scarce. Methods: In this retrospective multicenter cohort study derived from the FINE-TURK cohort, adults with DKD who initiated finerenone with baseline potassium ≥ 4.9 mEq/L were included. The primary outcome was clinically significant hyperkalemia (K ≥ 5.5 mEq/L) within three months. Multivariable logistic regression analyses were used to identify associated factors, with multiple sensitivity analyses performed. Results: A total of 166 patients were included, of whom 47 (28.3%) had baseline potassium levels between 5.1 and 5.5 mEq/L. Of the 166 patients, 35 (21.1%) reached the primary outcome, and 10 (6%) patients had follow-up potassium ≥ 6.0 mEq/L. 126 (76.8%) patients required no intervention, 24 (14.6%) were initiated on potassium binders, and finerenone was discontinued in only 12 (7.3%) patients. Lower baseline estimated glomerular filtration rate, baseline urinary albumin, loop diuretic use and 20 mg finerenone dose were associated with the primary outcome. In contrast, baseline potassium was not associated with the primary outcome. Conclusions: In patients with DKD and elevated baseline potassium levels, finerenone initiation was associated with manageable rates of hyperkalemia. Our findings support the cautious use of finerenone in selected patients under close monitoring, as well as highlight the need for a multidimensional approach to hyperkalemia risk assessment.
- 23 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (15) , 5758
Open AccessHyperkalemia Risk After Finerenone Initiation in Diabetic Kidney Disease with Elevated Baseline Potassium: A Multicenter Cohort Study
Background/Objectives: Finerenone improves cardiovascular and renal outcomes in diabetic kidney disease (DKD), but hyperkalemia remains a key safety concern. Patients with elevated baseline potassium levels (≥4.9 mEq/L) are largely excluded from clinical trials, and real-world data in this population are scarce. Methods: In this retrospective multicenter cohort study derived from the FINE-TURK cohort, adults with DKD who initiated finerenone with baseline potassium ≥ 4.9 mEq/L were included. The primary outcome was clinically significant hyperkalemia (K ≥ 5.5 mEq/L) within three months. Multivariable logistic regression analyses were used to identify associated factors, with multiple sensitivity analyses performed. Results: A total of 166 patients were included, of whom 47 (28.3%) had baseline potassium levels between 5.1 and 5.5 mEq/L. Of the 166 patients, 35 (21.1%) reached the primary outcome, and 10 (6%) patients had follow-up potassium ≥ 6.0 mEq/L. 126 (76.8%) patients required no intervention, 24 (14.6%) were initiated on potassium binders, and finerenone was discontinued in only 12 (7.3%) patients. Lower baseline estimated glomerular filtration rate, baseline urinary albumin, loop diuretic use and 20 mg finerenone dose were associated with the primary outcome. In contrast, baseline potassium was not associated with the primary outcome. Conclusions: In patients with DKD and elevated baseline potassium levels, finerenone initiation was associated with manageable rates of hyperkalemia. Our findings support the cautious use of finerenone in selected patients under close monitoring, as well as highlight the need for a multidimensional approach to hyperkalemia risk assessment.
- Open Access
- 7 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5285
Association Between the Uric Acid-to-Creatinine Ratio and Elevated Parathyroid Hormone Levels in Adults Without Known Parathyroid Disease
Background: Parathyroid hormone (PTH) is mainly regulated by calcium, vitamin D, and renal function, but metabolic factors may also influence its levels. The uric acid/creatinine (UA/Cr) ratio reflects uric acid metabolism and renal handling. This study evaluated its association with elevated PTH in adults without known parathyroid disease. Methods: This retrospective cross-sectional study included 244 adults undergoing routine biochemical evaluation. The uric acid-to-creatinine ratio (UA/Cr) was calculated. Participants were categorized according to PTH levels (≤65 pg/mL vs. >65 pg/mL). Logistic regression analyses were performed to identify factors associated with elevated PTH levels. Results: A total of 244 individuals (mean age 40.6 ± 11.7 years; 70.9% female) were included in the analysis. Participants with elevated PTH levels had significantly higher UA/Cr ratios compared with those with normal PTH levels (8.93 ± 1.82 vs. 7.47 ± 1.79, p = 0.031). In univariate logistic regression analysis, UA/Cr was associated with elevated PTH (OR 1.15, 95% CI 1.01–1.32, p = 0.043). In multivariable logistic regression analysis adjusting for vitamin D, magnesium, phosphorus, corrected calcium, age, sex, body mass index, and the estimated glomerular filtration rate, the UA/Cr ratio remained significantly associated with elevated PTH levels (OR 1.41, 95% CI 1.036–1.66, p = 0.024). Conclusions: The UA/Cr ratio was associated with elevated PTH levels in adults without known parathyroid disease, independently of vitamin D status, mineral metabolism parameters, and renal function. These findings suggest that the UA/Cr ratio may help characterize a broader metabolic context associated with elevated PTH levels, rather than serving as a diagnostic marker. Further prospective studies are needed to clarify the clinical relevance and direction of this association.
- 7 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5285
Open AccessAssociation Between the Uric Acid-to-Creatinine Ratio and Elevated Parathyroid Hormone Levels in Adults Without Known Parathyroid Disease
Background: Parathyroid hormone (PTH) is mainly regulated by calcium, vitamin D, and renal function, but metabolic factors may also influence its levels. The uric acid/creatinine (UA/Cr) ratio reflects uric acid metabolism and renal handling. This study evaluated its association with elevated PTH in adults without known parathyroid disease. Methods: This retrospective cross-sectional study included 244 adults undergoing routine biochemical evaluation. The uric acid-to-creatinine ratio (UA/Cr) was calculated. Participants were categorized according to PTH levels (≤65 pg/mL vs. >65 pg/mL). Logistic regression analyses were performed to identify factors associated with elevated PTH levels. Results: A total of 244 individuals (mean age 40.6 ± 11.7 years; 70.9% female) were included in the analysis. Participants with elevated PTH levels had significantly higher UA/Cr ratios compared with those with normal PTH levels (8.93 ± 1.82 vs. 7.47 ± 1.79, p = 0.031). In univariate logistic regression analysis, UA/Cr was associated with elevated PTH (OR 1.15, 95% CI 1.01–1.32, p = 0.043). In multivariable logistic regression analysis adjusting for vitamin D, magnesium, phosphorus, corrected calcium, age, sex, body mass index, and the estimated glomerular filtration rate, the UA/Cr ratio remained significantly associated with elevated PTH levels (OR 1.41, 95% CI 1.036–1.66, p = 0.024). Conclusions: The UA/Cr ratio was associated with elevated PTH levels in adults without known parathyroid disease, independently of vitamin D status, mineral metabolism parameters, and renal function. These findings suggest that the UA/Cr ratio may help characterize a broader metabolic context associated with elevated PTH levels, rather than serving as a diagnostic marker. Further prospective studies are needed to clarify the clinical relevance and direction of this association.
- Open Access
- 24 June 2026
- Published by MDPI AG in Preprints.org
Hyperkalemia Risk and Associated Factors After Finerenone Initiation in Patients with Diabetic Kidney Disease and Elevated Baseline Potassium: A Real-World Cohort Study
Background/Objectives: Finerenone improves cardiovascular and renal outcomes in diabetic kidney disease (DKD), but hyperkalemia remains a key safety concern. Patients with elevated baseline potassium levels (≥ 4.9 mEq/L) are largely excluded from clinical trials, and real-world data in this population are scarce. Methods: In this retrospective multicenter cohort study derived from the FINE-TURK cohort, adults with DKD who initiated finerenone with baseline serum potassium ≥ 4.9 mEq/L were included. The primary outcome was clinically significant hyperkalemia (CSH) (≥ 5.5 mEq/L) within three months. Multivariable logistic regression analyses were used to identify associated factors, with multiple sensitivity analyses performed. Results: 166 patients were included, of whom 47 (28.3%) had baseline potassium levels between 5.1 to 5.5 mEq/L. Of the 166 patients, 35 (21.1%) developed CSH, and 10 (6%) patients had follow-up potassium ≥ 6.0 mEq/L. 126 (76.8%) patients required no intervention, 24 (14.6%) were initiated on potassium binders, and finerenone was discontinued only in 12 (7.3%) patients. Baseline eGFR, baseline urinary albumin, loop diuretic use and 20mg finerenone dose were associated with CSH. In contrast, baseline serum potassium was not associated with CSH. Conclusions: In patients with DKD and elevated baseline potassium levels, finerenone initiation was associated with manageable rates of hyperkalemia. Our findings support the cautious use of finerenone in selected patients under close monitoring, as well as highlight the need for a multidimensional approach to hyperkalemia risk assessment.
- 24 June 2026
- Published by MDPI AG in Preprints.org
Open AccessHyperkalemia Risk and Associated Factors After Finerenone Initiation in Patients with Diabetic Kidney Disease and Elevated Baseline Potassium: A Real-World Cohort Study
Background/Objectives: Finerenone improves cardiovascular and renal outcomes in diabetic kidney disease (DKD), but hyperkalemia remains a key safety concern. Patients with elevated baseline potassium levels (≥ 4.9 mEq/L) are largely excluded from clinical trials, and real-world data in this population are scarce. Methods: In this retrospective multicenter cohort study derived from the FINE-TURK cohort, adults with DKD who initiated finerenone with baseline serum potassium ≥ 4.9 mEq/L were included. The primary outcome was clinically significant hyperkalemia (CSH) (≥ 5.5 mEq/L) within three months. Multivariable logistic regression analyses were used to identify associated factors, with multiple sensitivity analyses performed. Results: 166 patients were included, of whom 47 (28.3%) had baseline potassium levels between 5.1 to 5.5 mEq/L. Of the 166 patients, 35 (21.1%) developed CSH, and 10 (6%) patients had follow-up potassium ≥ 6.0 mEq/L. 126 (76.8%) patients required no intervention, 24 (14.6%) were initiated on potassium binders, and finerenone was discontinued only in 12 (7.3%) patients. Baseline eGFR, baseline urinary albumin, loop diuretic use and 20mg finerenone dose were associated with CSH. In contrast, baseline serum potassium was not associated with CSH. Conclusions: In patients with DKD and elevated baseline potassium levels, finerenone initiation was associated with manageable rates of hyperkalemia. Our findings support the cautious use of finerenone in selected patients under close monitoring, as well as highlight the need for a multidimensional approach to hyperkalemia risk assessment.
- Open Access
- 8 May 2026
- Published by MDPI AG in Preprints.org
Hyperkalemia Risk with Finerenone in Diabetic Kidney Disease: A Real-World Analysis from the FINE-TURK Cohort
Background: Finerenone is associated with a lower, yet clinically relevant, risk of hyperkalemia compared with steroidal mineralocorticoid receptor antagonists in diabetic kidney disease (DKD) trials. However, real-world data on hyperkalemia and its associated factors are lacking. Methodology: FINE-TURK is a national, observational cohort of DKD patients who were initiated on finerenone. Eligible adults were included; demographic, clinical, and laboratory data were evaluated. The primary outcome (PO) was hyperkalemia risk signal (potassium ≥ 5.0 mEq/L), and the secondary outcome (SO) was clinically meaningful hyperkalemia (potassium ≥ 5.5 mEq/L). Multivariate logistic regression (LR) was used to define features associated with both PO and SO. LR, random forest (RF), gradient boosting, and CatBoost classifiers were used to define important features associated with the PO. Results: 699 patients were included. 259 (37.1%) reached the PO, and 51 (7.3%) reached the SO. Baseline potassium and estimated glomerular filtration rate (eGFR) were the most important variables associated with both outcomes and were consistently identified as the top features across all models. Thiazide use, presence of diabetic retinopathy, and diabetes duration were also associated with the PO. LR demonstrated the highest recall; random forest achieved the highest precision in performance. Discussion: Real-world data suggest that the risk of clinically meaningful hyperkalemia is similar to that in the clinical trials. In parallel with the safety analysis of clinical trials, baseline potassium and eGFR were consistently the most important factors associated with hyperkalemia risk.
- 8 May 2026
- Published by MDPI AG in Preprints.org
Open AccessHyperkalemia Risk with Finerenone in Diabetic Kidney Disease: A Real-World Analysis from the FINE-TURK Cohort
Background: Finerenone is associated with a lower, yet clinically relevant, risk of hyperkalemia compared with steroidal mineralocorticoid receptor antagonists in diabetic kidney disease (DKD) trials. However, real-world data on hyperkalemia and its associated factors are lacking. Methodology: FINE-TURK is a national, observational cohort of DKD patients who were initiated on finerenone. Eligible adults were included; demographic, clinical, and laboratory data were evaluated. The primary outcome (PO) was hyperkalemia risk signal (potassium ≥ 5.0 mEq/L), and the secondary outcome (SO) was clinically meaningful hyperkalemia (potassium ≥ 5.5 mEq/L). Multivariate logistic regression (LR) was used to define features associated with both PO and SO. LR, random forest (RF), gradient boosting, and CatBoost classifiers were used to define important features associated with the PO. Results: 699 patients were included. 259 (37.1%) reached the PO, and 51 (7.3%) reached the SO. Baseline potassium and estimated glomerular filtration rate (eGFR) were the most important variables associated with both outcomes and were consistently identified as the top features across all models. Thiazide use, presence of diabetic retinopathy, and diabetes duration were also associated with the PO. LR demonstrated the highest recall; random forest achieved the highest precision in performance. Discussion: Real-world data suggest that the risk of clinically meaningful hyperkalemia is similar to that in the clinical trials. In parallel with the safety analysis of clinical trials, baseline potassium and eGFR were consistently the most important factors associated with hyperkalemia risk.
- Open Access
- 1 September 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-8
The effect of tolvaptan on renal progression and systemic inflammation in ADPKD
Inflammation plays a crucial role in the progression of autosomal dominant polycystic kidney disease (ADPKD). While tolvaptan is primarily known for its vasopressin V2 receptor antagonism, its potential anti-inflammatory effects remain under investigation. This study aimed to evaluate the impact of tolvaptan on inflammatory markers and renal progression in ADPKD patients. This retrospective, two-center cohort study included 80 ADPKD patients, with 40 receiving tolvaptan and 40 serving as controls. Inflammatory markers, including C-reactive protein (CRP), systemic inflammatory index (SII), platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and renal function parameters such as glomerular filtration rate (GFR) and proteinuria, were analyzed over a 1-year follow-up period. In the tolvaptan group, CRP, SII, PLR, proteinuria, and uric acid levels significantly decreased, whereas these markers increased in the control group. GFR remained stable in the tolvaptan group but declined significantly in the control group (p < 0.001). No significant correlation was found between GFR and inflammatory markers in either group. Our findings suggest that tolvaptan may contribute to reducing systemic inflammation in ADPKD patients while preserving renal function. These results align with previous studies indicating a link between inflammation and ADPKD progression.
- 1 September 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-8
Open AccessThe effect of tolvaptan on renal progression and systemic inflammation in ADPKD
Inflammation plays a crucial role in the progression of autosomal dominant polycystic kidney disease (ADPKD). While tolvaptan is primarily known for its vasopressin V2 receptor antagonism, its potential anti-inflammatory effects remain under investigation. This study aimed to evaluate the impact of tolvaptan on inflammatory markers and renal progression in ADPKD patients. This retrospective, two-center cohort study included 80 ADPKD patients, with 40 receiving tolvaptan and 40 serving as controls. Inflammatory markers, including C-reactive protein (CRP), systemic inflammatory index (SII), platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and renal function parameters such as glomerular filtration rate (GFR) and proteinuria, were analyzed over a 1-year follow-up period. In the tolvaptan group, CRP, SII, PLR, proteinuria, and uric acid levels significantly decreased, whereas these markers increased in the control group. GFR remained stable in the tolvaptan group but declined significantly in the control group (p < 0.001). No significant correlation was found between GFR and inflammatory markers in either group. Our findings suggest that tolvaptan may contribute to reducing systemic inflammation in ADPKD patients while preserving renal function. These results align with previous studies indicating a link between inflammation and ADPKD progression.
- Open Access
- 28 July 2025
- Published by Galenos Yayinevi in European Journal of Geriatrics and Gerontology
Relationship Between Frailty and Quality of Life and Pain Levels in Older Patients Undergoing Hemodialysis
Relationship Between Frailty and Quality of Life and Pain Levels in Older Patients Undergoing Hemodialysis - European Journal of Geriatrics and Gerontology
- 28 July 2025
- Published by Galenos Yayinevi in European Journal of Geriatrics and Gerontology
Open AccessRelationship Between Frailty and Quality of Life and Pain Levels in Older Patients Undergoing Hemodialysis
Relationship Between Frailty and Quality of Life and Pain Levels in Older Patients Undergoing Hemodialysis - European Journal of Geriatrics and Gerontology
- Open Access
- 25 October 2023
- Published by Selcuk University in Genel Tıp Dergisi
- Vol. 33 (5) , 481-484
The Effect of Sleep Quality of Patients Under Hemodialysis on Death Anxiety, Depression and Pain
Background/Aims: Poor sleep quality in hemodialysis patients causes a decrease in quality of life. In this study we aimed to investigate the relationship between sleep quality, and depression, death anxiety and perceived pain. Methods: A total of 101 patients with chronic kidney disease (CKD) under hemodialysis were included in this cross-sectional study. The assessment tools were Beck Depression Inventory (BDI), Death Anxiety Scale (DAS), Pittsburgh Sleep Quality Index (PSQI), and Visual Analogue Scale (VAS). Results: The mean age of the patients was 51.9±13.1. Ninety six (95%) patients had a PSQI score of 6 or above that indicates poor sleep quality. 64.4% of the patients had mild to severe depressive symptoms in terms of BDI. There were significant correlations between PSQI and DAS (r: 0.382), and VAS (r: 0.261), and BDI (r: 0.483). Conclusion: Poor sleep quality is a common problem in hemodialysis patients. Death anxiety, pain and depression are associated with poor sleep in hemodialysis patients. It is recommended to consider poor sleep quality to provide appropriate treatment.
- 25 October 2023
- Published by Selcuk University in Genel Tıp Dergisi
- Vol. 33 (5) , 481-484
Open AccessThe Effect of Sleep Quality of Patients Under Hemodialysis on Death Anxiety, Depression and Pain
Background/Aims: Poor sleep quality in hemodialysis patients causes a decrease in quality of life. In this study we aimed to investigate the relationship between sleep quality, and depression, death anxiety and perceived pain. Methods: A total of 101 patients with chronic kidney disease (CKD) under hemodialysis were included in this cross-sectional study. The assessment tools were Beck Depression Inventory (BDI), Death Anxiety Scale (DAS), Pittsburgh Sleep Quality Index (PSQI), and Visual Analogue Scale (VAS). Results: The mean age of the patients was 51.9±13.1. Ninety six (95%) patients had a PSQI score of 6 or above that indicates poor sleep quality. 64.4% of the patients had mild to severe depressive symptoms in terms of BDI. There were significant correlations between PSQI and DAS (r: 0.382), and VAS (r: 0.261), and BDI (r: 0.483). Conclusion: Poor sleep quality is a common problem in hemodialysis patients. Death anxiety, pain and depression are associated with poor sleep in hemodialysis patients. It is recommended to consider poor sleep quality to provide appropriate treatment.
- 5 July 2023
- Published by Elsevier in Transplantation Proceedings
- Vol. 55 (7) , 1551-1554
Effects of Induction Therapy on Graft Functions in Terms of Immunologic Risk
- 5 July 2023
- Published by Elsevier in Transplantation Proceedings
- Vol. 55 (7) , 1551-1554
Effects of Induction Therapy on Graft Functions in Terms of Immunologic Risk
- Open Access
- 26 May 2023
- Published by New Trends in Medicine Sciences in New Trends in Medicine Sciences
- Vol. 4 (2) , 83-88
The Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratios of Pregnant Women Who Underwent the 75-g Oral Glucose Tolerance Test to Predict Gestational Diabetes
Background: Gestational diabetes mellitus (GDM) is one of the most common medical complications of pregnancy. Early diagnosis and treatment are important; the condition can cause both maternal and foetal complications. Today, single-/double-bolus oral 50–100-g glucose tolerance tests (OGTTs) are preferred. We explored whether the peripheral blood platelet/lymphocyte ratio (PLR) and/or neutrophil/lymphocyte ratio (NLR) could guide diabetes screening of a target group (rather than all pregnant women). Materials and Methods: This retrospective study was conducted at the Obstetrics and Gynecology Clinic of Sanko University Hospital from January 2010 to January 2020. Pregnant women in gestational weeks 24 to 28 who underwent 75-g OGTTs were included. Patients were evaluated by dividing them into two groups. Group 1 included 300 women with GDM. Group 2 included 300 healthy pregnant women who were negative on the OGTT test. We retrieved patient ages, gestational weeks, all blood count data derived during pregnancy, fasting blood glucose levels, heights and weights, and body mass indices. Results: Leukocyte and neutrophil counts were significantly higher in the diabetic patient group than in the control group (both p < 0.01). The NLR and PLR differed significantly between the two groups (both p < 0.01), but the demographic data did not. Conclusion: Increase in white blood cell count, and elevations in the PLR and NLR, independently predicted GDM. Blood NLR and PLR can also be used as a GDM screening test. The NLR and PLR (markers of inflammation) were significantly increased in pre-diabetic and diabetic patients. The NLR and PLR may usefully predict pre-diabetes and GDM.
- 26 May 2023
- Published by New Trends in Medicine Sciences in New Trends in Medicine Sciences
- Vol. 4 (2) , 83-88
Open AccessThe Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratios of Pregnant Women Who Underwent the 75-g Oral Glucose Tolerance Test to Predict Gestational Diabetes
Background: Gestational diabetes mellitus (GDM) is one of the most common medical complications of pregnancy. Early diagnosis and treatment are important; the condition can cause both maternal and foetal complications. Today, single-/double-bolus oral 50–100-g glucose tolerance tests (OGTTs) are preferred. We explored whether the peripheral blood platelet/lymphocyte ratio (PLR) and/or neutrophil/lymphocyte ratio (NLR) could guide diabetes screening of a target group (rather than all pregnant women). Materials and Methods: This retrospective study was conducted at the Obstetrics and Gynecology Clinic of Sanko University Hospital from January 2010 to January 2020. Pregnant women in gestational weeks 24 to 28 who underwent 75-g OGTTs were included. Patients were evaluated by dividing them into two groups. Group 1 included 300 women with GDM. Group 2 included 300 healthy pregnant women who were negative on the OGTT test. We retrieved patient ages, gestational weeks, all blood count data derived during pregnancy, fasting blood glucose levels, heights and weights, and body mass indices. Results: Leukocyte and neutrophil counts were significantly higher in the diabetic patient group than in the control group (both p < 0.01). The NLR and PLR differed significantly between the two groups (both p < 0.01), but the demographic data did not. Conclusion: Increase in white blood cell count, and elevations in the PLR and NLR, independently predicted GDM. Blood NLR and PLR can also be used as a GDM screening test. The NLR and PLR (markers of inflammation) were significantly increased in pre-diabetic and diabetic patients. The NLR and PLR may usefully predict pre-diabetes and GDM.
- Open Access
- 8 February 2023
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 1(77),p. 13-18
Relationship between dialysis adequacy and cognitive function in hemodialysis patients
The prevalence of cognitive impairment is extremely high in dialysis patients, and it has been hypothesized that low urea clearance has an impact on cognitive impairment. However, several other studies conducted in the era of high-flux dialysis have not shown an association between lower Kt/V and poorer cognitive function. Therefore, studies that directly examine the relationship between dialysis adequacy and cognitive function in hemodialysis patients are essential. The present study aimed to investigate the cognitive functions of hemodialysis patients and their relationship with dialysis adequacy. Methods. This cross-sectional observational study included 100 patients and 100 healthy volunteers. Dialysis adequacy was assessed by the Kt/V ratio in the previous month. The Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment Test (MoCA), and the Clock Drawing Test (CDT) were used to assess cognitive function. Multiple regression analysis was used to determine the significant association between the cognitive assessments and the independent variables (Kt/V, age, education, hemoglobin, and albumin). Results. There were no significant differences between patients and controls in age and sex. Patients had a mean Kt/V ratio of 1.52±0.29. MMSE, MoCA, and CDT were lower in patients than in controls. There were strong positive correlations between MMSE and Kt/V (r = 0.81), MoCA and Kt/V (r = 0.84), CDT and Kt/V (r = 0.79). Conclusion. Cognitive functions in hemodialysis patients were significantly decreased compared with healthy controls and associated with dialysis adequacy. Dialysis adequacy should be questioned in patients with low cognitive function.
- 8 February 2023
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 1(77),p. 13-18
Open AccessRelationship between dialysis adequacy and cognitive function in hemodialysis patients
The prevalence of cognitive impairment is extremely high in dialysis patients, and it has been hypothesized that low urea clearance has an impact on cognitive impairment. However, several other studies conducted in the era of high-flux dialysis have not shown an association between lower Kt/V and poorer cognitive function. Therefore, studies that directly examine the relationship between dialysis adequacy and cognitive function in hemodialysis patients are essential. The present study aimed to investigate the cognitive functions of hemodialysis patients and their relationship with dialysis adequacy. Methods. This cross-sectional observational study included 100 patients and 100 healthy volunteers. Dialysis adequacy was assessed by the Kt/V ratio in the previous month. The Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment Test (MoCA), and the Clock Drawing Test (CDT) were used to assess cognitive function. Multiple regression analysis was used to determine the significant association between the cognitive assessments and the independent variables (Kt/V, age, education, hemoglobin, and albumin). Results. There were no significant differences between patients and controls in age and sex. Patients had a mean Kt/V ratio of 1.52±0.29. MMSE, MoCA, and CDT were lower in patients than in controls. There were strong positive correlations between MMSE and Kt/V (r = 0.81), MoCA and Kt/V (r = 0.84), CDT and Kt/V (r = 0.79). Conclusion. Cognitive functions in hemodialysis patients were significantly decreased compared with healthy controls and associated with dialysis adequacy. Dialysis adequacy should be questioned in patients with low cognitive function.